Month: June 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) — Hudson Capital Inc. (NASDAQ: HUSN) (Hudson Capital) announced that FreightHub, Inc. (Fr8Hub), a North American transportation logistics technology platform company focused on US-Mexico cross-border shipping with which Hudson Capital has signed a definitive Merger Agreement, is collaborating with RC Control to help alleviate one of the biggest challenges with US-Mexico cross border freight: seamless visibility. “The Fr8Hub Mobile App provides 24/7 visibility to our users and RC Control’s integration complements our mobile app to help give customers increased confidence that they will be able to have the same experience tracking their freight on either side of the US-Mexico border,” stated Javier Selgas, CEO of Fr8Hub. “Now our carriers, both in the US and Mexico, have multiple options for...

NEWTOWN, Pa., June 02, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the appointment of Frederick Fantazzia to the position of Vice President of Sales & Marketing, North America, effective June 1, 2021. “Fred is a dynamic leader with 16 years of sales and marketing experience in the field of neuromodulation, and a specific focus on developing the market for new neuromodulation technologies by building and leading high-quality sales team to raise awareness and facilitate commercial adoption,” said Dane Andreeff, Interim President and Chief Executive Officer of Helius. “We are pleased to welcome him to our leadership team and look forward to his contributions as we continue our pre-commercialization...

Global Will be Using All CLIA WAIVED Lab to Test for COVID 19 Antigen, Antibody, and the Other 15 Tests that are CLIA WAIVED that Global Carries; Company is Bringing Testing to Patients at Schools & Work SAN CLEMENTE, CA, June 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire – Global WholeHealth Partners Corp. (OTC: GWHP), a company that offers one of the largest lines of COVID 19 tests including SARS-CoV-2 viruses and that states that its Antibody IgG/IgM tests that they offer are capable of detecting all the current identified SARS-CoV-2 viruses, today announced that they will be bringing their tests directly to the homes and offices of patients in need. To help implement this outreach program, the Company has signed an agreement with Dr. Vu Le to be the Medical Director for the Company’s CLIA WAIVED Mobile Laboratory. The Company...

Orlando, Florida, June 02, 2021 (GLOBE NEWSWIRE) — Immune Therapeutics Inc. (OTC-PINK: IMUND) (the “Company”) announced today that the Company has received and signed a non-binding term sheet to enter into an agreement that would provide working capital and wipe out a significant portion of its long-standing Debt. The Company received the term sheet from existing Immune Shareholders to provide the funds necessary to complete the restructuring of Immune. According to the agreement, the investors will lend a minimum of $700,000 and a maximum of $1,500,000 to the Company in exchange for non-convertible promissory notes bearing interest at 5%. In connection with the transactions above, to the extent a noteholder holds any warrants to purchase shares of common stock of Borrower (“Warrants”), Lender shall have the right...

UPPSALA, Sweden, June 02, 2021 (GLOBE NEWSWIRE) — Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Signature Q100, to allow more researchers access to Olink technology and high-quality proteomics data. Olink Signature Q100 is an affordable new benchtop system designed for readout of Olink® Target and Olink® Focus protein biomarker panels. In parallel with the successful implementation of the Olink Explore platform for high-throughput protein biomarker discovery with Next-Generation Sequencing (NGS) readout, Olink continues to invest in and develop its portfolio of more targeted solutions for protein biomarker research, based on readout with microfluidic quantitative PCR (qPCR). Until now, readout of Olink’s Target and Focus panels has been exclusively carried out using the multi-functional...

DALLAS, June 02, 2021 (GLOBE NEWSWIRE) — Rapid Therapeutic Science Laboratories, Inc. (OTC Pink: RTSL) an SEC fully-reporting, growth-oriented aerosol manufacturing company focused on delivery of non-psychoactive cannabinoid compounds, announced today it has executed two (2) contracts to conduct Phase 1 human clinical trials of its flagship metered dose inhaler (MDI) containing Cannabidiol (CBD). RTSL entered into these two contracts in preparation for filing an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA). Filing is anticipated in the next 30 days. An IND is a request for the FDA’s authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. RTSL engaged Dr. Charles Powell, MD who is the Chief...

SPRINGDALE, Ark., June 02, 2021 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN) announced today that Chief Operating Officer Donnie King has been named President and Chief Executive Officer, effective immediately. Current President and CEO Dean Banks is leaving the company and board for personal reasons. “The board and I know that Donnie has a deep understanding of our business, values and culture and the solid leadership skills needed to continue to implement our strategy and deliver strong results,” said John H. Tyson, chairman of the board. “We want to express our appreciation to Dean for his contributions as a board member and executive.” “Being a part of Tyson Foods has been a very rewarding experience,” said Banks. “Upon deep personal reflection, and discussions with my family, the board, and my colleagues, I believe that...

NEW BRAUNFELS, Texas, June 02, 2021 (GLOBE NEWSWIRE) — TaskUs, Inc. (“TaskUs” or the “Company”) announced today the launch of its initial public offering of 13,200,000 shares of its Class A common stock to be sold by TaskUs and certain of its stockholders. The initial public offering price is currently expected to be between $22.00 and $24.00 per share. The selling stockholders expect to grant the underwriters a 30-day option to purchase up to an additional 1,980,000 shares of Class A common stock. TaskUs intends to list its common stock on Nasdaq Global Select Market under the symbol “TASK.” TaskUs intends to use the net proceeds received by it from this offering, together with cash on hand, to satisfy payments of approximately $127.4 million in respect of vested phantom shares held by certain current and former employees that...